The Federal Trade Commission has approved Spain-based global healthcare company Grifols S.A.’s acquisition of Florida-based Biotest US Corp. on a condition that the company divest certain of its assets.
FTC has asked Grifols to sell of blood plasma collection centers in three U.S. cities, among other conditions, as part of a settlement resolving charges that Grifols’ acquisition is anticompetitive and violates federal antitrust law.
The FTC required blood plasma collection centers to be divested in Augusta, Georgia; Lincoln, Nebraska; and Youngstown, Ohio to KedPlasma, which is a subsidiary of Kedrion Biopharma Inc.
Biotest Wednesday announced that Grifols has completed its acquisition of Biotest USA for $286 Million in cash. The acquisition comprises 22 Biotest plasma collection centers, 2 centers under construction and 2 centers under purchase contract as well as corporate offices located in Boca Raton, Florida and more than 900 US employees.
“We are excited to be part of the Grifols prestigious global organization and remain steadfast on our mission to secure a quality supply of the raw materials needed to help the thousands of patients that rely on plasma based therapies,” said Ileana Carlisle, BPC’s Chief Executive Officer.
by RTTNews Staff Writer
Source: Read Full Article